123707

: Because cases of infant botulism can fluctuate by up to 60% annually , any unspent funds at the end of a fiscal year are automatically carried forward. This "rainy day" provision ensures that when an outbreak occurs, the resources are already in place.

: To ensure rapid response, the department is exempt from standard competitive bidding for the testing and distribution of the treatment. 123707

Governed by California Health and Safety Code § 123707 , the Infant Botulism Treatment and Prevention Unit isn't just a regulatory body—it’s a manufacturer. It is the primary entity authorized to handle the distribution and licensure of Botulism Immune Globulin Intravenous (Human) , often referred to by its trade name, BabyBIG®. : Because cases of infant botulism can fluctuate

AI responses may include mistakes. For legal advice, consult a professional. Learn more California Code, Health and Safety Code - HSC § 123707 Governed by California Health and Safety Code §

The number refers to California Health and Safety Code § 123707 , which governs the Infant Botulism Treatment and Prevention Unit . This unit is responsible for the manufacture, distribution, and licensure of Botulism Immune Globulin Intravenous (Human) , a life-saving treatment for infants.

The law provides this unit with extraordinary flexibility because the stakes are so high. According to the statute: